About us
Van Leeuwenhoeck Research (VLR) is an independent research company, enabling institutional investors and other professional investors to better understand the real value of innovative Life Sciences companies they invest in. VLR can tap into a selected circle of top analysts in L...
Published by: Marcel Wijma |
Date: 29 August 2010
Van Leeuwenhoeck Research, Inc. (VLR) announced that it has launched a new monthly magazine called LS Tribune. The new publication, edited by Founder and Chief Executive Officer Marcel Wijma, will detail news and developments in the global biotech and pharmaceutical industries.
|
Published by: Marcel Wijma |
Date: 24 July 2010
Dutch/Danish biotech company Genmab saw a strong rebound in its share price of more than 50% from a low of DKK 40. The primary reason for this in our opinion was due to the outcome of a renegotiated partnership with GSK on Arzerra. This provides Genmab with a upfront payment of STG 90 million. The payment is inclusive of the reduced R&D expenses for Genmab on Arzerra, giving Genmab much needed financial stability and also the first sign towards earning back its investors trust. More to follow.
|